Scalper1 News
Shares of biotechs Celgene (CELG) and Infinity Pharmaceuticals (INFI) were both up in the stock market today on strong clinical data on their blood-cancer drugs presented at the American Society of Hematology conference over the weekend. Celgene reported details from its MM020 trial of Revlimid, which is already a blockbuster approved for treating relapsed multiple myeloma. The trial is studying the risk/benefit profile of Revlimid for long-term Scalper1 News
Scalper1 News